Global Cell-Free Circulating Tumor DNA (ctDNA) Market Growth (Status and Outlook) 2026-2032
The global Cell-Free Circulating Tumor DNA (ctDNA) market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Cell-free circulating tumor DNA (ctDNA) can act as a noninvasive cancer biomarker, offering a potential alternative to invasive tissue biopsies.
United States market for Cell-Free Circulating Tumor DNA (ctDNA) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Cell-Free Circulating Tumor DNA (ctDNA) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Cell-Free Circulating Tumor DNA (ctDNA) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Cell-Free Circulating Tumor DNA (ctDNA) players cover Nexomics, Roche, ORIOMICS, Signatera, Illumina, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the ?Cell-Free Circulating Tumor DNA (ctDNA) Industry Forecast? looks at past sales and reviews total world Cell-Free Circulating Tumor DNA (ctDNA) sales in 2025, providing a comprehensive analysis by region and market sector of projected Cell-Free Circulating Tumor DNA (ctDNA) sales for 2026 through 2032. With Cell-Free Circulating Tumor DNA (ctDNA) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cell-Free Circulating Tumor DNA (ctDNA) industry.
This Insight Report provides a comprehensive analysis of the global Cell-Free Circulating Tumor DNA (ctDNA) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Cell-Free Circulating Tumor DNA (ctDNA) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Cell-Free Circulating Tumor DNA (ctDNA) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cell-Free Circulating Tumor DNA (ctDNA) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cell-Free Circulating Tumor DNA (ctDNA).
This report presents a comprehensive overview, market shares, and growth opportunities of Cell-Free Circulating Tumor DNA (ctDNA) market by product type, application, key players and key regions and countries.
Segmentation by Type:
Cell-free circulating tumor DNA (ctDNA) can act as a noninvasive cancer biomarker, offering a potential alternative to invasive tissue biopsies.
United States market for Cell-Free Circulating Tumor DNA (ctDNA) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Cell-Free Circulating Tumor DNA (ctDNA) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Cell-Free Circulating Tumor DNA (ctDNA) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Cell-Free Circulating Tumor DNA (ctDNA) players cover Nexomics, Roche, ORIOMICS, Signatera, Illumina, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the ?Cell-Free Circulating Tumor DNA (ctDNA) Industry Forecast? looks at past sales and reviews total world Cell-Free Circulating Tumor DNA (ctDNA) sales in 2025, providing a comprehensive analysis by region and market sector of projected Cell-Free Circulating Tumor DNA (ctDNA) sales for 2026 through 2032. With Cell-Free Circulating Tumor DNA (ctDNA) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cell-Free Circulating Tumor DNA (ctDNA) industry.
This Insight Report provides a comprehensive analysis of the global Cell-Free Circulating Tumor DNA (ctDNA) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Cell-Free Circulating Tumor DNA (ctDNA) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Cell-Free Circulating Tumor DNA (ctDNA) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cell-Free Circulating Tumor DNA (ctDNA) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cell-Free Circulating Tumor DNA (ctDNA).
This report presents a comprehensive overview, market shares, and growth opportunities of Cell-Free Circulating Tumor DNA (ctDNA) market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Gastric Cancer Methylation Screening
- Esophageal Cancer Methylation Screening
- Colorectal Cancer Methylation Screening
- Lung Cancer Methylation Screening
- Liver Cancer Methylation Screening
- Other Cancer Screening
- Hospital
- Medical Center
- Laboratory
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Nexomics
- Roche
- ORIOMICS
- Signatera
- Illumina
- Sysmex Corporation
- Bio-Rad
- Biocartis
- QIAGEN
- GuardantHealth
- GSK plc
- AstraZeneca
- NeoGenomics Laboratories
- AmoyDx
- Annoroad
- Burning Rock Biotech
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032)
2.1.2 Cell-Free Circulating Tumor DNA (ctDNA) Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Cell-Free Circulating Tumor DNA (ctDNA) by Country/Region (2021, 2025 & 2032)
2.2 Cell-Free Circulating Tumor DNA (ctDNA) Segment by Type
2.2.1 Gastric Cancer Methylation Screening
2.2.2 Esophageal Cancer Methylation Screening
2.2.3 Colorectal Cancer Methylation Screening
2.2.4 Lung Cancer Methylation Screening
2.2.5 Liver Cancer Methylation Screening
2.2.6 Other Cancer Screening
2.2.7 Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type
2.2.7.1 Cell-Free Circulating Tumor DNA (ctDNA) Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.7.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Type (2021-2026)
2.3 Cell-Free Circulating Tumor DNA (ctDNA) Segment by Application
2.3.1 Hospital
2.3.2 Medical Center
2.3.3 Laboratory
2.3.4 Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application
2.3.4.1 Cell-Free Circulating Tumor DNA (ctDNA) Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Application (2021-2026)
3 CELL-FREE CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE BY PLAYER
3.1 Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Player
3.1.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Player (2021-2026)
3.1.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Player (2021-2026)
3.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 CELL-FREE CIRCULATING TUMOR DNA (CTDNA) BY REGION
4.1 Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2021-2026)
4.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Annual Revenue by Country/Region (2021-2026)
4.3 Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth (2021-2026)
4.4 APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth (2021-2026)
4.5 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth (2021-2026)
4.6 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026)
5.2 Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026)
5.3 Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2021-2026)
6.2 APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026)
6.3 APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026)
7.2 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026)
7.3 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) by Region (2021-2026)
8.2 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026)
8.3 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL CELL-FREE CIRCULATING TUMOR DNA (CTDNA) MARKET FORECAST
10.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Forecast by Region (2027-2032)
10.1.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Forecast by Region (2027-2032)
10.1.2 Americas Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.1.3 APAC Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.1.4 Europe Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.1.5 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.2 Americas Cell-Free Circulating Tumor DNA (ctDNA) Forecast by Country (2027-2032)
10.2.1 United States Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.2.2 Canada Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.2.3 Mexico Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.2.4 Brazil Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.3 APAC Cell-Free Circulating Tumor DNA (ctDNA) Forecast by Region (2027-2032)
10.3.1 China Cell-Free Circulating Tumor DNA (ctDNA) Market Forecast
10.3.2 Japan Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.3.3 Korea Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.3.4 Southeast Asia Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.3.5 India Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.3.6 Australia Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.4 Europe Cell-Free Circulating Tumor DNA (ctDNA) Forecast by Country (2027-2032)
10.4.1 Germany Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.4.2 France Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.4.3 UK Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.4.4 Italy Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.4.5 Russia Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.5 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Forecast by Region (2027-2032)
10.5.1 Egypt Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.5.2 South Africa Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.5.3 Israel Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.5.4 Turkey Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.6 Global Cell-Free Circulating Tumor DNA (ctDNA) Forecast by Type (2027-2032)
10.7 Global Cell-Free Circulating Tumor DNA (ctDNA) Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
11 KEY PLAYERS ANALYSIS
11.1 Nexomics
11.1.1 Nexomics Company Information
11.1.2 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.1.3 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Nexomics Main Business Overview
11.1.5 Nexomics Latest Developments
11.2 Roche
11.2.1 Roche Company Information
11.2.2 Roche Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.2.3 Roche Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Roche Main Business Overview
11.2.5 Roche Latest Developments
11.3 ORIOMICS
11.3.1 ORIOMICS Company Information
11.3.2 ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.3.3 ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 ORIOMICS Main Business Overview
11.3.5 ORIOMICS Latest Developments
11.4 Signatera
11.4.1 Signatera Company Information
11.4.2 Signatera Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.4.3 Signatera Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Signatera Main Business Overview
11.4.5 Signatera Latest Developments
11.5 Illumina
11.5.1 Illumina Company Information
11.5.2 Illumina Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.5.3 Illumina Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Illumina Main Business Overview
11.5.5 Illumina Latest Developments
11.6 Sysmex Corporation
11.6.1 Sysmex Corporation Company Information
11.6.2 Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.6.3 Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Sysmex Corporation Main Business Overview
11.6.5 Sysmex Corporation Latest Developments
11.7 Bio-Rad
11.7.1 Bio-Rad Company Information
11.7.2 Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.7.3 Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Bio-Rad Main Business Overview
11.7.5 Bio-Rad Latest Developments
11.8 Biocartis
11.8.1 Biocartis Company Information
11.8.2 Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.8.3 Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Biocartis Main Business Overview
11.8.5 Biocartis Latest Developments
11.9 QIAGEN
11.9.1 QIAGEN Company Information
11.9.2 QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.9.3 QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 QIAGEN Main Business Overview
11.9.5 QIAGEN Latest Developments
11.10 GuardantHealth
11.10.1 GuardantHealth Company Information
11.10.2 GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.10.3 GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 GuardantHealth Main Business Overview
11.10.5 GuardantHealth Latest Developments
11.11 GSK plc
11.11.1 GSK plc Company Information
11.11.2 GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.11.3 GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 GSK plc Main Business Overview
11.11.5 GSK plc Latest Developments
11.12 AstraZeneca
11.12.1 AstraZeneca Company Information
11.12.2 AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.12.3 AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 AstraZeneca Main Business Overview
11.12.5 AstraZeneca Latest Developments
11.13 NeoGenomics Laboratories
11.13.1 NeoGenomics Laboratories Company Information
11.13.2 NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.13.3 NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 NeoGenomics Laboratories Main Business Overview
11.13.5 NeoGenomics Laboratories Latest Developments
11.14 AmoyDx
11.14.1 AmoyDx Company Information
11.14.2 AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.14.3 AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 AmoyDx Main Business Overview
11.14.5 AmoyDx Latest Developments
11.15 Annoroad
11.15.1 Annoroad Company Information
11.15.2 Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.15.3 Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Annoroad Main Business Overview
11.15.5 Annoroad Latest Developments
11.16 Burning Rock Biotech
11.16.1 Burning Rock Biotech Company Information
11.16.2 Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.16.3 Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Burning Rock Biotech Main Business Overview
11.16.5 Burning Rock Biotech Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032)
2.1.2 Cell-Free Circulating Tumor DNA (ctDNA) Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Cell-Free Circulating Tumor DNA (ctDNA) by Country/Region (2021, 2025 & 2032)
2.2 Cell-Free Circulating Tumor DNA (ctDNA) Segment by Type
2.2.1 Gastric Cancer Methylation Screening
2.2.2 Esophageal Cancer Methylation Screening
2.2.3 Colorectal Cancer Methylation Screening
2.2.4 Lung Cancer Methylation Screening
2.2.5 Liver Cancer Methylation Screening
2.2.6 Other Cancer Screening
2.2.7 Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type
2.2.7.1 Cell-Free Circulating Tumor DNA (ctDNA) Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.7.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Type (2021-2026)
2.3 Cell-Free Circulating Tumor DNA (ctDNA) Segment by Application
2.3.1 Hospital
2.3.2 Medical Center
2.3.3 Laboratory
2.3.4 Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application
2.3.4.1 Cell-Free Circulating Tumor DNA (ctDNA) Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Application (2021-2026)
3 CELL-FREE CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE BY PLAYER
3.1 Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Player
3.1.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Player (2021-2026)
3.1.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Player (2021-2026)
3.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 CELL-FREE CIRCULATING TUMOR DNA (CTDNA) BY REGION
4.1 Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2021-2026)
4.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Annual Revenue by Country/Region (2021-2026)
4.3 Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth (2021-2026)
4.4 APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth (2021-2026)
4.5 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth (2021-2026)
4.6 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026)
5.2 Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026)
5.3 Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2021-2026)
6.2 APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026)
6.3 APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026)
7.2 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026)
7.3 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) by Region (2021-2026)
8.2 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026)
8.3 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL CELL-FREE CIRCULATING TUMOR DNA (CTDNA) MARKET FORECAST
10.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Forecast by Region (2027-2032)
10.1.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Forecast by Region (2027-2032)
10.1.2 Americas Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.1.3 APAC Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.1.4 Europe Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.1.5 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.2 Americas Cell-Free Circulating Tumor DNA (ctDNA) Forecast by Country (2027-2032)
10.2.1 United States Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.2.2 Canada Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.2.3 Mexico Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.2.4 Brazil Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.3 APAC Cell-Free Circulating Tumor DNA (ctDNA) Forecast by Region (2027-2032)
10.3.1 China Cell-Free Circulating Tumor DNA (ctDNA) Market Forecast
10.3.2 Japan Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.3.3 Korea Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.3.4 Southeast Asia Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.3.5 India Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.3.6 Australia Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.4 Europe Cell-Free Circulating Tumor DNA (ctDNA) Forecast by Country (2027-2032)
10.4.1 Germany Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.4.2 France Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.4.3 UK Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.4.4 Italy Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.4.5 Russia Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.5 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Forecast by Region (2027-2032)
10.5.1 Egypt Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.5.2 South Africa Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.5.3 Israel Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.5.4 Turkey Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
10.6 Global Cell-Free Circulating Tumor DNA (ctDNA) Forecast by Type (2027-2032)
10.7 Global Cell-Free Circulating Tumor DNA (ctDNA) Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
11 KEY PLAYERS ANALYSIS
11.1 Nexomics
11.1.1 Nexomics Company Information
11.1.2 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.1.3 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Nexomics Main Business Overview
11.1.5 Nexomics Latest Developments
11.2 Roche
11.2.1 Roche Company Information
11.2.2 Roche Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.2.3 Roche Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Roche Main Business Overview
11.2.5 Roche Latest Developments
11.3 ORIOMICS
11.3.1 ORIOMICS Company Information
11.3.2 ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.3.3 ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 ORIOMICS Main Business Overview
11.3.5 ORIOMICS Latest Developments
11.4 Signatera
11.4.1 Signatera Company Information
11.4.2 Signatera Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.4.3 Signatera Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Signatera Main Business Overview
11.4.5 Signatera Latest Developments
11.5 Illumina
11.5.1 Illumina Company Information
11.5.2 Illumina Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.5.3 Illumina Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Illumina Main Business Overview
11.5.5 Illumina Latest Developments
11.6 Sysmex Corporation
11.6.1 Sysmex Corporation Company Information
11.6.2 Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.6.3 Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Sysmex Corporation Main Business Overview
11.6.5 Sysmex Corporation Latest Developments
11.7 Bio-Rad
11.7.1 Bio-Rad Company Information
11.7.2 Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.7.3 Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Bio-Rad Main Business Overview
11.7.5 Bio-Rad Latest Developments
11.8 Biocartis
11.8.1 Biocartis Company Information
11.8.2 Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.8.3 Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Biocartis Main Business Overview
11.8.5 Biocartis Latest Developments
11.9 QIAGEN
11.9.1 QIAGEN Company Information
11.9.2 QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.9.3 QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 QIAGEN Main Business Overview
11.9.5 QIAGEN Latest Developments
11.10 GuardantHealth
11.10.1 GuardantHealth Company Information
11.10.2 GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.10.3 GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 GuardantHealth Main Business Overview
11.10.5 GuardantHealth Latest Developments
11.11 GSK plc
11.11.1 GSK plc Company Information
11.11.2 GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.11.3 GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 GSK plc Main Business Overview
11.11.5 GSK plc Latest Developments
11.12 AstraZeneca
11.12.1 AstraZeneca Company Information
11.12.2 AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.12.3 AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 AstraZeneca Main Business Overview
11.12.5 AstraZeneca Latest Developments
11.13 NeoGenomics Laboratories
11.13.1 NeoGenomics Laboratories Company Information
11.13.2 NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.13.3 NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 NeoGenomics Laboratories Main Business Overview
11.13.5 NeoGenomics Laboratories Latest Developments
11.14 AmoyDx
11.14.1 AmoyDx Company Information
11.14.2 AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.14.3 AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 AmoyDx Main Business Overview
11.14.5 AmoyDx Latest Developments
11.15 Annoroad
11.15.1 Annoroad Company Information
11.15.2 Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.15.3 Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Annoroad Main Business Overview
11.15.5 Annoroad Latest Developments
11.16 Burning Rock Biotech
11.16.1 Burning Rock Biotech Company Information
11.16.2 Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
11.16.3 Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Burning Rock Biotech Main Business Overview
11.16.5 Burning Rock Biotech Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Cell-Free Circulating Tumor DNA (ctDNA) Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Cell-Free Circulating Tumor DNA (ctDNA) Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Gastric Cancer Methylation Screening
Table 4. Major Players of Esophageal Cancer Methylation Screening
Table 5. Major Players of Colorectal Cancer Methylation Screening
Table 6. Major Players of Lung Cancer Methylation Screening
Table 7. Major Players of Liver Cancer Methylation Screening
Table 8. Major Players of Other Cancer Screening
Table 9. Cell-Free Circulating Tumor DNA (ctDNA) Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026) & ($ millions)
Table 11. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Type (2021-2026)
Table 12. Cell-Free Circulating Tumor DNA (ctDNA) Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 13. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026) & ($ millions)
Table 14. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Application (2021-2026)
Table 15. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Player (2021-2026) & ($ millions)
Table 16. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Player (2021-2026)
Table 17. Cell-Free Circulating Tumor DNA (ctDNA) Key Players Head office and Products Offered
Table 18. Cell-Free Circulating Tumor DNA (ctDNA) Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 19. New Products and Potential Entrants
Table 20. Mergers & Acquisitions, Expansion
Table 21. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2021-2026) & ($ millions)
Table 22. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Region (2021-2026)
Table 23. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country/Region (2021-2026) & ($ millions)
Table 24. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Country/Region (2021-2026)
Table 25. Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026) & ($ millions)
Table 26. Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Country (2021-2026)
Table 27. Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026) & ($ millions)
Table 28. Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Type (2021-2026)
Table 29. Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026) & ($ millions)
Table 30. Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Application (2021-2026)
Table 31. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2021-2026) & ($ millions)
Table 32. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Region (2021-2026)
Table 33. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026) & ($ millions)
Table 34. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026) & ($ millions)
Table 35. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026) & ($ millions)
Table 36. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Country (2021-2026)
Table 37. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026) & ($ millions)
Table 38. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026) & ($ millions)
Table 39. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2021-2026) & ($ millions)
Table 40. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026) & ($ millions)
Table 41. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026) & ($ millions)
Table 42. Key Market Drivers & Growth Opportunities of Cell-Free Circulating Tumor DNA (ctDNA)
Table 43. Key Market Challenges & Risks of Cell-Free Circulating Tumor DNA (ctDNA)
Table 44. Key Industry Trends of Cell-Free Circulating Tumor DNA (ctDNA)
Table 45. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Region (2027-2032) & ($ millions)
Table 46. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share Forecast by Region (2027-2032)
Table 47. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Type (2027-2032) & ($ millions)
Table 48. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Application (2027-2032) & ($ millions)
Table 49. Nexomics Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 50. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 51. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 52. Nexomics Main Business
Table 53. Nexomics Latest Developments
Table 54. Roche Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 55. Roche Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 56. Roche Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 57. Roche Main Business
Table 58. Roche Latest Developments
Table 59. ORIOMICS Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 60. ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 61. ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 62. ORIOMICS Main Business
Table 63. ORIOMICS Latest Developments
Table 64. Signatera Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 65. Signatera Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 66. Signatera Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 67. Signatera Main Business
Table 68. Signatera Latest Developments
Table 69. Illumina Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 70. Illumina Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 71. Illumina Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 72. Illumina Main Business
Table 73. Illumina Latest Developments
Table 74. Sysmex Corporation Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 75. Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 76. Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 77. Sysmex Corporation Main Business
Table 78. Sysmex Corporation Latest Developments
Table 79. Bio-Rad Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 80. Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 81. Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 82. Bio-Rad Main Business
Table 83. Bio-Rad Latest Developments
Table 84. Biocartis Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 85. Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 86. Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 87. Biocartis Main Business
Table 88. Biocartis Latest Developments
Table 89. QIAGEN Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 90. QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 91. QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 92. QIAGEN Main Business
Table 93. QIAGEN Latest Developments
Table 94. GuardantHealth Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 95. GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 96. GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 97. GuardantHealth Main Business
Table 98. GuardantHealth Latest Developments
Table 99. GSK plc Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 100. GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 101. GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 102. GSK plc Main Business
Table 103. GSK plc Latest Developments
Table 104. AstraZeneca Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 105. AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 106. AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 107. AstraZeneca Main Business
Table 108. AstraZeneca Latest Developments
Table 109. NeoGenomics Laboratories Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 110. NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 111. NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 112. NeoGenomics Laboratories Main Business
Table 113. NeoGenomics Laboratories Latest Developments
Table 114. AmoyDx Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 115. AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 116. AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 117. AmoyDx Main Business
Table 118. AmoyDx Latest Developments
Table 119. Annoroad Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 120. Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 121. Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 122. Annoroad Main Business
Table 123. Annoroad Latest Developments
Table 124. Burning Rock Biotech Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 125. Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 126. Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 127. Burning Rock Biotech Main Business
Table 128. Burning Rock Biotech Latest Developments
Table 1. Cell-Free Circulating Tumor DNA (ctDNA) Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Cell-Free Circulating Tumor DNA (ctDNA) Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Gastric Cancer Methylation Screening
Table 4. Major Players of Esophageal Cancer Methylation Screening
Table 5. Major Players of Colorectal Cancer Methylation Screening
Table 6. Major Players of Lung Cancer Methylation Screening
Table 7. Major Players of Liver Cancer Methylation Screening
Table 8. Major Players of Other Cancer Screening
Table 9. Cell-Free Circulating Tumor DNA (ctDNA) Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026) & ($ millions)
Table 11. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Type (2021-2026)
Table 12. Cell-Free Circulating Tumor DNA (ctDNA) Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 13. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026) & ($ millions)
Table 14. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Application (2021-2026)
Table 15. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Player (2021-2026) & ($ millions)
Table 16. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Player (2021-2026)
Table 17. Cell-Free Circulating Tumor DNA (ctDNA) Key Players Head office and Products Offered
Table 18. Cell-Free Circulating Tumor DNA (ctDNA) Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 19. New Products and Potential Entrants
Table 20. Mergers & Acquisitions, Expansion
Table 21. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2021-2026) & ($ millions)
Table 22. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Region (2021-2026)
Table 23. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country/Region (2021-2026) & ($ millions)
Table 24. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Country/Region (2021-2026)
Table 25. Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026) & ($ millions)
Table 26. Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Country (2021-2026)
Table 27. Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026) & ($ millions)
Table 28. Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Type (2021-2026)
Table 29. Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026) & ($ millions)
Table 30. Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Application (2021-2026)
Table 31. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2021-2026) & ($ millions)
Table 32. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Region (2021-2026)
Table 33. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026) & ($ millions)
Table 34. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026) & ($ millions)
Table 35. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026) & ($ millions)
Table 36. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Country (2021-2026)
Table 37. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026) & ($ millions)
Table 38. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026) & ($ millions)
Table 39. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2021-2026) & ($ millions)
Table 40. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026) & ($ millions)
Table 41. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026) & ($ millions)
Table 42. Key Market Drivers & Growth Opportunities of Cell-Free Circulating Tumor DNA (ctDNA)
Table 43. Key Market Challenges & Risks of Cell-Free Circulating Tumor DNA (ctDNA)
Table 44. Key Industry Trends of Cell-Free Circulating Tumor DNA (ctDNA)
Table 45. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Region (2027-2032) & ($ millions)
Table 46. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share Forecast by Region (2027-2032)
Table 47. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Type (2027-2032) & ($ millions)
Table 48. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Application (2027-2032) & ($ millions)
Table 49. Nexomics Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 50. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 51. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 52. Nexomics Main Business
Table 53. Nexomics Latest Developments
Table 54. Roche Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 55. Roche Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 56. Roche Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 57. Roche Main Business
Table 58. Roche Latest Developments
Table 59. ORIOMICS Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 60. ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 61. ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 62. ORIOMICS Main Business
Table 63. ORIOMICS Latest Developments
Table 64. Signatera Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 65. Signatera Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 66. Signatera Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 67. Signatera Main Business
Table 68. Signatera Latest Developments
Table 69. Illumina Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 70. Illumina Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 71. Illumina Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 72. Illumina Main Business
Table 73. Illumina Latest Developments
Table 74. Sysmex Corporation Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 75. Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 76. Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 77. Sysmex Corporation Main Business
Table 78. Sysmex Corporation Latest Developments
Table 79. Bio-Rad Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 80. Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 81. Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 82. Bio-Rad Main Business
Table 83. Bio-Rad Latest Developments
Table 84. Biocartis Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 85. Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 86. Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 87. Biocartis Main Business
Table 88. Biocartis Latest Developments
Table 89. QIAGEN Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 90. QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 91. QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 92. QIAGEN Main Business
Table 93. QIAGEN Latest Developments
Table 94. GuardantHealth Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 95. GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 96. GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 97. GuardantHealth Main Business
Table 98. GuardantHealth Latest Developments
Table 99. GSK plc Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 100. GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 101. GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 102. GSK plc Main Business
Table 103. GSK plc Latest Developments
Table 104. AstraZeneca Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 105. AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 106. AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 107. AstraZeneca Main Business
Table 108. AstraZeneca Latest Developments
Table 109. NeoGenomics Laboratories Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 110. NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 111. NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 112. NeoGenomics Laboratories Main Business
Table 113. NeoGenomics Laboratories Latest Developments
Table 114. AmoyDx Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 115. AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 116. AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 117. AmoyDx Main Business
Table 118. AmoyDx Latest Developments
Table 119. Annoroad Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 120. Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 121. Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 122. Annoroad Main Business
Table 123. Annoroad Latest Developments
Table 124. Burning Rock Biotech Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors
Table 125. Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
Table 126. Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 127. Burning Rock Biotech Main Business
Table 128. Burning Rock Biotech Latest Developments
LIST OF FIGURES
Figure 1. Cell-Free Circulating Tumor DNA (ctDNA) Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Cell-Free Circulating Tumor DNA (ctDNA) Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Cell-Free Circulating Tumor DNA (ctDNA) Sales Market Share by Country/Region (2025)
Figure 8. Cell-Free Circulating Tumor DNA (ctDNA) Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Type in 2025
Figure 10. Cell-Free Circulating Tumor DNA (ctDNA) in Hospital
Figure 11. Global Cell-Free Circulating Tumor DNA (ctDNA) Market: Hospital (2021-2026) & ($ millions)
Figure 12. Cell-Free Circulating Tumor DNA (ctDNA) in Medical Center
Figure 13. Global Cell-Free Circulating Tumor DNA (ctDNA) Market: Medical Center (2021-2026) & ($ millions)
Figure 14. Cell-Free Circulating Tumor DNA (ctDNA) in Laboratory
Figure 15. Global Cell-Free Circulating Tumor DNA (ctDNA) Market: Laboratory (2021-2026) & ($ millions)
Figure 16. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Application in 2025
Figure 17. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Player in 2025
Figure 18. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Region (2021-2026)
Figure 19. Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2021-2026 ($ millions)
Figure 20. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2021-2026 ($ millions)
Figure 21. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2021-2026 ($ millions)
Figure 23. Americas Cell-Free Circulating Tumor DNA (ctDNA) Value Market Share by Country in 2025
Figure 24. United States Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Region in 2025
Figure 29. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Type (2021-2026)
Figure 30. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Application (2021-2026)
Figure 31. China Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 35. India Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Country in 2025
Figure 38. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Type (2021-2026)
Figure 39. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Application (2021-2026)
Figure 40. Germany Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 41. France Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 54. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 55. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 57. United States Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 58. Canada Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 59. Mexico Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 60. Brazil Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 61. China Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 62. Japan Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 63. Korea Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 65. India Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 66. Australia Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 67. Germany Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 68. France Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 69. UK Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 70. Italy Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 71. Russia Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 72. Egypt Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 73. South Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 74. Israel Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 75. Turkey Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 76. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 1. Cell-Free Circulating Tumor DNA (ctDNA) Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Cell-Free Circulating Tumor DNA (ctDNA) Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Cell-Free Circulating Tumor DNA (ctDNA) Sales Market Share by Country/Region (2025)
Figure 8. Cell-Free Circulating Tumor DNA (ctDNA) Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Type in 2025
Figure 10. Cell-Free Circulating Tumor DNA (ctDNA) in Hospital
Figure 11. Global Cell-Free Circulating Tumor DNA (ctDNA) Market: Hospital (2021-2026) & ($ millions)
Figure 12. Cell-Free Circulating Tumor DNA (ctDNA) in Medical Center
Figure 13. Global Cell-Free Circulating Tumor DNA (ctDNA) Market: Medical Center (2021-2026) & ($ millions)
Figure 14. Cell-Free Circulating Tumor DNA (ctDNA) in Laboratory
Figure 15. Global Cell-Free Circulating Tumor DNA (ctDNA) Market: Laboratory (2021-2026) & ($ millions)
Figure 16. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Application in 2025
Figure 17. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Player in 2025
Figure 18. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Region (2021-2026)
Figure 19. Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2021-2026 ($ millions)
Figure 20. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2021-2026 ($ millions)
Figure 21. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2021-2026 ($ millions)
Figure 23. Americas Cell-Free Circulating Tumor DNA (ctDNA) Value Market Share by Country in 2025
Figure 24. United States Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Region in 2025
Figure 29. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Type (2021-2026)
Figure 30. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Application (2021-2026)
Figure 31. China Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 35. India Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Country in 2025
Figure 38. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Type (2021-2026)
Figure 39. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Application (2021-2026)
Figure 40. Germany Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 41. France Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 54. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 55. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 57. United States Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 58. Canada Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 59. Mexico Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 60. Brazil Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 61. China Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 62. Japan Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 63. Korea Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 65. India Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 66. Australia Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 67. Germany Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 68. France Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 69. UK Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 70. Italy Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 71. Russia Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 72. Egypt Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 73. South Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 74. Israel Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 75. Turkey Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
Figure 76. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 ($ millions)
